OptiBiotix Ltd Directorate Changes

OptiBiotix Health plc

("OptiBiotix" or the "Company")

OptiBiotix Ltd Directorate Changes

Appointment of Non-Executive Director of OptiBiotix Ltd

OptiBiotix Health plc (AIM: OPTI, OTCQB: OPTBF), a life sciences business developing products which reduce hunger and food cravings, enhance the gut microbiome, and sweet fibres as healthy sugar substitutes announces the appointment of Imad Farhat as a non-executive director (NED) of OptiBiotix Ltd, a wholly owned subsidiary of OptiBiotix Health plc, with immediate effect. OptiBiotix Ltd contains OptiBiotix's SlimBiome®, SweetBiotix®, and microbiome modulating technology platforms.

Imad has more than 30 years' experience in science and business and joins from the position of Head of Taste and WellBeing for South Asia, Middle East, and Africa at Givaudan.  Givaudan is a Swiss multinational and a global leader in Fragrance & Beauty and Taste & Wellbeing markets. In his role at Givaudan, Imad led all aspects of strategy, technical development, commercialisation, and sales of the Taste business in over 68 countries.  Prior to joining Givaudan Imad was Senior Vice President of Speciality Ingredients at Del Monte Corporation (NYSE: DMC), and Senior Vice President Taste, Global Head of Sugar Reduction at dsm-firmenich and board member of Avansya, a partnership between Cargill and dsm-firmenich developing and commercialising sweeteners. Imad held several senior roles at Firmenich in Europe, US and Asia.  Prior to dsm-firmenich, he was Senior Lecturer at the University of Nottingham.  Imad has a PhD in food science, an MSc and BSc in chemistry, and has over 70 scientific publications and is a contributor to industry and governmental advisory panels and a frequent speaker at global conferences.

Imad has a wealth of technical and commercial experiences in the Taste and Wellbeing industries at senior executive level. With a background in science and business he brings extensive experience in developing products and commercial experience in taking sugar alternative products to market. Imad has a strong track record in driving sales growth and profitability and has been involved in a number of acquisitions in support of accelerating business growth.

Imad is multilingual in English, French, and Arabic.  His international experience and his global network of manufacturing, distribution, and sales contacts in the sweetness and sugar replacement industry will support the commercialisation of OptiBiotix's SweetBiotix and other products

Imad's appointment is part of the continued evolution of the OptiBiotix Ltd board in line with the Company's strategic focus on commercialising it's second-generation product portfolio.

Stephen O'Hara, CEO of OptiBiotix, commented: "Imad's scientific knowledge and experience of commercialising new products to a profitable business, coupled with his global network of industry contacts within the Taste and Wellbeing industry will help OptiBiotix in its next phase of evolution.  Having established international sales and brand awareness of its award-winning satiety inducing SlimBiome® product the Company is now turning its focus on commercialising its innovative second generation SweetBiotix® and microbiome modulating products. Imad's expertise and experience in senior executive roles for global corporates like Givaudan, dsm-firmenich, and Del Monte Corp. within the Taste and Wellness industry brings new skills, expertise, and insight to OptiBiotix to support the next stage of its development"

View the full announcement and submit questions to management via our website: 

https://optibiotix.com/link/y5nYqe

About OptiBiotix - www.optibiotix.com

OptiBiotix Health plc (AIM: OPTI, OTCQB: OPTBF), has developed a range of technologies and commercialised products which modulate the human microbiome to help prevent and manage human disease.  Since the Group's inception it has created a wide range of microbiome-based ingredients and products including prebiotic products like SlimBiome®, WellBiome®, SweetBiotix® and Microbiome Modulators within its core OptiBiotix Health plc (OPTI) business, but also skincare through its holdings in SkinBioTherapeutics PLC (SBTX), and probiotics through ProBiotix Health plc (PBX). These companies create a diverse portfolio of technologies and products in an emerging area of healthcare that is of growing interest in consumer markets throughout the world.

This communication is a "Reach" announcement. Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained in this announcement is of a non-regulatory nature. Information required to be notified under the AIM Rules for Companies, Market Abuse Regulation or other regulation would be disseminated as an RNS regulatory announcement and not on RNS Reach.